Brokerage Firm Rating Update on Globus Medical (GMED)

Globus Medical (GMED) has an average broker rating of 2.18, which is interpreted as a Buy, as rated by 11 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.

Globus Medical (GMED) : The highest level Globus Medical (GMED) is projected to reach is $33 for the short term and the lowest estimate is at $23. The consolidated price target from 8 rating analysts who initiate coverage on the stock is $26.75 and the possibility the share price can swing is $3.24.


For the current week, the company shares have a recommendation consensus of Buy. Also, Morgan Stanley maintains their rating on the shares of Globus Medical (NYSE:GMED). The current rating of the shares is Equal-weight. Equity Analysts at the Firm lowers the price target to $25 per share from $28 per share. The rating by the firm was issued on July 28, 2016.

Globus Medical (NYSE:GMED): stock was range-bound between the intraday low of $24.14 and the intraday high of $24.48 after having opened at $24.22 on Wednesdays session. The stock finally closed in the red at $24.22, a loss of -0.41%. The stock remained in the red for the whole trading day. The total traded volume was 562,926 shares. The stock failed to cross $24.48 in Wednesdays trading. The stocks closing price on Thursday was $24.26.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.